We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Gemphire Therapeutics Inc | NASDAQ:GEMP | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.30 | 0.30 | 0.3169 | 0 | 01:00:00 |
From Jul 2019 to Jul 2024
| Canaccord Genuity Growth Conference 2017 | |
| Date: | Wednesday, August 9 |
| Time: | 2:30pm Eastern Time |
| Presenter: | Lee Golden, MD, Chief Medical Officer |
| Location: | InterContinental Boston, Paris Room |
| Webcast: | http://wsw.com/webcast/canaccord26/gemp |
A webcast replay will be available on the News & Events section of the Gemphire website for all interested parties following the presentation and will be archived and available for 90 days. The slide presentation used during the conference will be posted to the Gemphire corporate website on August 9.
About GemphireGemphire is a clinical-stage biopharmaceutical company that is committed to helping patients with cardiometabolic disorders, including dyslipidemia and NASH. The Company is focused on providing new treatment options for cardiometabolic diseases through its complementary, convenient, cost-effective product candidate gemcabene as add-on to the standard of care especially statins that will benefit patients, physicians, and payors. Gemphire has initiated 3 clinical trials for homozygous familial hypercholesterolemia (HoFH), heterozygous familial hypercholesterolemia (HeFH)/atherosclerotic cardiovascular disease (ASCVD), and severe hypertriglyceridemia (SHTG) under NCT02722408, NCT02634151, and NCT02944383, respectively with a fourth planned trial in NASH to initiate in second half of 2017. Please visit www.gemphire.com for more information.
Contact: Andrew McDonald, Ph.D. LifeSci Advisors, LLC (646) 597-6987 Jeff Mathiesen, CFO Gemphire Therapeutics Inc. (734) 245-1700
1 Year Gemphire Therapeutics Chart |
1 Month Gemphire Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
